Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer

Next Previous
X
Search
Trial Profile

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Chemotherapy-induced damage; Febrile neutropenia
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin Korea; Kyowa Kirin

    • Most Recent Events

    • 30 Aug 2021 Status changed from recruiting to completed.
    • 01 Mar 2020 Planned End Date changed from 1 Jul 2020 to 1 Jun 2021.
    • 01 Mar 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top